secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moderna, Inc. (MRNA)
CIK:        0001682852
Form:       8-K
Filed at:   2026-01-05T23:59:59+00:00
Accession:  0001682852-26-000003
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moderna projects 2025 revenue $1.6-2.0B, targets up to 10% growth in 2026
-------------------------------------------------------------------------

- 2025 revenue guidance of $1.6-2.0B; cash costs beat commitments by nearly $1B.
- mNEXSPIKE captured ~24% of U.S. retail COVID shots and ~33% of 65+ segment.
- Secured $1.5B five-year term loan; GAAP opex to fall below $5.5B in 2025 from $7.2B in 2024.
- Cash cost target: ~$4.2B in 2026 and $3.5-3.9B in 2027; cash breakeven targeted in 2028.
- Pipeline: Phase 3 flu efficacy positive; intismeran Phase 2b data and nine oncology readouts expected.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1682852/000168285226000003/0001682852-26-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1682852/000168285226000003/mrna-20260105.htm
  HTML page:      https://secwatch.observer/filing/0001682852-26-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer